Mucosal vaccines delivered by nose or throat as sniffable or inhalable formulations could offer long-term COVID immunity. Several are in clinical trials.
A new study has shown that levels of coronavirus antibodies have decreased in the UK over a three-month period, leading to questions over how long immunity from COVID-19 lasts.
Des études sur des patients atteints de COVID-19 ont révélé que des réponses immunitaires agressives au coronavirus peuvent provoquer une grave inflammation.
Mientras que el acceso a la atención sanitaria, la exposición laboral y los riesgos ambientales como la contaminación afectan a la tasa de supervivencia, para muchos grupos de riesgo, el ...
While access to healthcare, occupational exposure and environmental risks such as pollution all affect survival rate, for many at-risk groups, the key factor is inflammation.
